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ABSTRACT  
Schizophrenia occurs in about one in four individuals with 22q11.2 deletion syndrome 
(22q11.2DS). The aim of this International Brain and Behavior 22q11.2DS Consortium (IBBC) 
study was to identify genetic factors that contribute to schizophrenia, in addition to the ~20-fold 
increased risk conveyed by the 22q11.2 deletion. Using whole-genome sequencing data from 519 
unrelated individuals with 22q11.2DS, we conducted genome-wide comparisons of common and 
rare variants between those with schizophrenia and those with no psychotic disorder at age ≥25 
years. Available microarray data enabled direct comparison of polygenic risk for schizophrenia 
between 22q11.2DS and independent population samples with no 22q11.2 deletion, with and 
without schizophrenia (total n=35,182). Polygenic risk for schizophrenia within 22q11.2DS was 
significantly greater for those with schizophrenia (padj=6.73x10
-6). Novel reciprocal case-control 
comparisons between the 22q11.2DS and population-based cohorts showed that polygenic risk 
score was significantly greater in individuals with psychotic illness, regardless of the presence of 
the 22q11.2 deletion. Within the 22q11.2DS cohort, results of gene-set analyses showed some 
support for rare variants affecting synaptic genes. No common or rare variants within the 22q11.2 
deletion region were significantly associated with schizophrenia.  These findings suggest that in 
addition to conferring a greatly increased risk to schizophrenia, the risk is higher when the 
22q11.2 deletion and common polygenic risk factors that contribute to schizophrenia in the 
general population are both present.  
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INTRODUCTION  
There is accumulated evidence that the recurrent 22q11.2 deletion associated with 22q11.2 
deletion syndrome (22q11.2DS) represents a clinically relevant cause of schizophrenia, and is 
one of the strongest known risk factors for schizophrenia (1). Schizophrenia occurs in about one 
in four individuals with 22q11.2DS, representing a more than 20-fold increase over the general 
population risk of 1% (1, 2). Identifying additional genetic modifiers of expressing schizophrenia 
in addition to the deletion is of scientific and clinical interest (1, 3, 4). 
Discovering such additional genetic factors is a primary goal of the International 22q11.2DS 
Brain and Behavior Consortium (IBBC) (3). We recently reported evidence from genome-wide 
microarray data that other rare copy number variations (CNVs) outside of the 22q11.2 deletion 
region increase risk to schizophrenia in 22q11.2DS (5). A key question is whether other genetic 
contributions to schizophrenia, known to exert risk in the general population, are modifying risk 
of schizophrenia within the 22q11.2DS subgroup.  
Schizophrenia is polygenic, with risk variants spanning the full spectrum of population 
frequencies. Common alleles identified from genome-wide association studies (GWAS) each 
contribute only a small effect to disease risk, but their aggregate effect can confer a far greater 
risk, quantifiable as a polygenic risk score (PRS). Analyzing by aggregating genes can also be a 
means to observe relevant associations (6). Studies of rare protein-coding variants implicate 
functional gene-sets relevant to neuronal functions and synaptic components including the 
activity-regulated cytoskeleton-associated protein (ARC) complex, amongst others (7-12).  
The current study used whole genome sequencing and microarray data from the IBBC (3) to 
investigate the contribution of common (single nucleotide polymorphisms, SNPs) and rare 
genetic variants (comprising mostly single nucleotide variants (SNVs) in protein-coding regions 
of genes), i.e., sequence variant classes with prior evidence from idiopathic schizophrenia (8, 9, 
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13). To improve power, we examined collective signals imparted by the schizophrenia PRS for 
SNPs (6, 13), and functional gene-sets (10) for rare variants. We examined these variant effects 
both within the 22q11.2 deletion region and genome-wide, comparing individuals with 
schizophrenia and related major psychotic disorders to those with no psychotic disorder and aged 
≥25 years, therefore largely past the age at greatest risk for onset of psychotic illness.  
 
METHODS 
Sample collection and diagnostic classification 
The IBBC ascertainment and assessment methods have been previously detailed (3, 5). Briefly, 
individuals with a presumed 22q11.2 deletion, who were recruited from 22 international sites in 
studies approved by local institutional research ethics boards, and for whom existing DNA 
samples were available, were ascertained for the study. The focus of this study was on unrelated 
individuals with sufficient data to discern psychotic illness status, who were molecularly 
confirmed to have a typical hemizygous deletion at 22q11.2, i.e., that spanned the LCR22A-
LCR22B region, most commonly extending from LCR22A-LCR22D (1, 3). As before, 
individuals were eligible for inclusion in this study if they met DSM diagnostic criteria for a 
major psychotic disorder (mostly schizophrenia) at any age, or had no history of any psychotic 
illness when assessed at age ≥25 years (5). Subjects with affective psychosis were excluded. A 
case consensus procedure assured stringent diagnostic categorization (3). Additional details are 
provided in the Supplement.  
Whole-genome sequencing (WGS) and processing of DNA samples  
Raw Illumina WGS data were mapped with PEMapper (14) to genome build GRCh38/hg38 with 
a median sequencing depth of 39X. The 22q11.2 deletion region was called based on sequencing 
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depth, and variants were called independently with PECaller (14) for the genome-wide diploid 
and 22q11.2 haploid regions of the genomes. Routine QC metrics were performed (Table S1) and 
resulted in a multi-ethnic sample of 519 subjects (259 schizophrenia, 260 no psychotic illness). 
Using principal component analysis anchored with HapMap reference samples to infer ancestry, 
we further defined a European subsample of 435 subjects (214 schizophrenia, 221 no psychotic 
illness) based on subjects whose principal components were within 1 standard deviation of the 
average PC value for HapMap3 CEU subjects. Additional details on principal components and 
related QC are provided in the Supplement. These samples were then used for subsequent variant 
annotation and analyses.  
Additional samples and array-based genotyping for polygenic risk assessment 
An important aspect of our study was to assess the contribution of polygenic risk to schizophrenia 
in 22q11.2DS given previous results for schizophrenia in the general population (13).  
To achieve this, we used an idiopathic schizophrenia case-control study (CLOZUK/WTCCC) 
(15) where samples were independent of those from the schizophrenia case-control training 
dataset used for PRS construction (6). To allow comparisons between the PRS derived from this 
dataset and our 22q11.2DS cohort, we used available Affymetrix Genome-Wide Human SNP 6.0 
array genotype data (5, 16). Analyses were restricted to samples of European ancestry and 
autosomal SNPs. Identity by descent analysis identified three subjects from the 22q11.2DS 
cohort who were also present in the CLOZUK cohort. After excluding these individuals there 
were 432 (212 with schizophrenia; 220 non-psychotic controls) individuals from the 22q11.2DS 
cohort included for the primary PRS and rare variant analyses. 
After alignment (HRCv1.1) (17) and phasing with Eagle2 (18), genotype imputation of the 
22q11.2DS cohort was performed using Minimac3 (19). SNPs with common variants (MAF 
>10%), low missingness (<1%), HWE mid p >10-5 and high imputation quality (INFO >0.9) were 
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retained for PRS analysis. PRS results obtained from imputed SNP data were compared to those 
obtained from WGS data using a sub-sample of 365 individuals (171 with schizophrenia; 194 
non-psychotic) that had passed QC for both methods. Identity by descent analysis ensured 
correspondence between samples. Only overlapping SNPs that had passed QC in both datasets 
were kept for this analysis. 
 
To establish a homogenous dataset that would enable a joint analysis of the array-based data from 
22q11.2DS and CLOZUK/WTCCC, we initially conducted a QC step that used SNPs that were 
shared between both datasets (see Supplement for additional details). Following principal 
component analysis, samples >6 standard deviations from the mean of first 20 principal 
components were excluded to ensure homogeneity of the merged 22q11.2DS and 
CLOZUK/WTCCC datasets of European ancestry. This QC resulted in a dataset of 322 
individuals with 22q11.2DS (147 with schizophrenia; 175 non-psychotic controls), 10,791 
schizophrenia CLOZUK cases and 24,391 WTCCC controls for joint PRS analyses.  
Statistical analyses 
Single-variant association analysis of common variants: We performed association analyses of 
WGS data using PLINK 1.9. Variants were defined as common if sample MAF was either ≥1% 
outside the 22q11.2 deletion, or ≥2% within the 22q11.2 deletion (given the inherent reduction in 
the number of haploid variants observed). For analysis within the 22q11.2 deletion region, we 
only considered hemizygous SNPs, ie SNPs located in the deleted region. We therefore 
performed two sets of analyses: one where all individuals were included and where we 
considered SNPs located in the region spanning LCR22A-LCR22B, as this region is deleted in all 
study participants; and one where only individuals with the larger LCR22A-LCR22D deletion 
were included, using SNPs spanning that entire interval. We used logistic regression to regress 
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disease status on a variant (additive coding), adjusting for sex and top principal components of 
ancestry. For analyses of the entire sample (n=519: 259 schizophrenia, 260 no psychotic illness), 
we adjusted for top 5 principal components derived from this sample plus HapMap reference 
samples (Fig. SF1). For analyses of the European subset (n=435: 214 schizophrenia, 221 no 
psychotic illness), we adjusted for the top 3 principal components derived from this subset. Given 
the possibility of unreliable asymptotic results for variants with sample MAF of 1-5%, we further 
studied these variants using Fisher’s Exact Test.  
Polygenic risk score (PRS) analyses: We used PRSice software (PRSice-2) (20) to construct PRS 
in the European subset. We compared WGS and array data to assess robustness of results. Two 
different datasets were used as the discovery (training) sample. For the 22q11.2DS-only analyses 
(n=432) that used WGS data, we used summary results from the second Psychiatric Genomics 
Consortium mega-analysis of schizophrenia (PGC2 SCZ) (13). For the analysis of 22q11.2DS 
(n=322) and CLOZUK/WTCCC cohorts (n=10,791/24,391) that used array data, we used a 
version of the PGC2 SCZ data that excluded the CLOZUK/WTCCC samples (6). Only autosomal 
SNPs with high imputation quality (INFO > 0.9) were kept in these discovery datasets. In all 
target datasets, we used only variants with MAF >10% and excluded variants from the X 
chromosome, the 22q11.2 deletion region, and the Major Histocompatibility Complex (due to 
complex linkage disequilibrium patterns in the region) to calculate PRS. We also excluded 
ambiguous SNPs (A/T and C/G) that posed challenges in matching between discovery and 
validation sets. Specific coordinates of excluded regions are described in the Supplement. 
Using PRSice, we clumped SNPs from the discovery datasets (R2 >0.1, 250 kb window), and 
then selected clumped SNPs at 13 P-value thresholds (ranging from <10-6 to 1). For each P-value 
threshold, PRSice constructed a PRS for each individual from the target datasets as an average of 
the per-allele score for each eligible SNP. The per-allele score for a SNP was calculated as half 
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the product of the number of reference alleles (0, 1 or 2) and the estimated log odds ratio for the 
SNP in the discovery dataset.  
For the 22q11.2DS-only analysis using WGS data, we used logistic regression to test for 
association between disease status and standardized PRS adjusting for the same covariates (sex, 
top 3 principal components for ancestry) as for the analyses of individual common variants 
above. For the 22q11.2DS-CLOZUK/WTCCC joint analysis, we adjusted for sex and the top 3 
principal components from the array data. For the PRS comparison between WGS and array data 
the same number of covariates were used (top 3 principal components for ancestry and sex) but 
using the principal components from each respective dataset. For all models, we used PRSice-2 
to calculate both odds ratios per standard deviation of PRS as well as Nagelkerke’s pseudo-R2 
values to estimate the proportion of variance in schizophrenia explained by the PRS. We adjusted 
for testing of multiple correlated PRSs under different p-value thresholds using the P_ACT 
method (21).  
Rare variant analyses: Rare variant analyses were conducted on the 432 subjects in the European 
subset used for PRS analysis. We defined rare variants as those with gnomAD global frequency 
≤1% and 22q11.2DS sample frequency ≤1% for all variants, but analyzed those from the 22q11.2 
deletion region separately (Table S2). We also performed analyses using 5 different sets of 
filtered variants, based on: 1) any variant with Combined Annotation Dependent Depletion, 
CADD,(17) >30, 2) any variant with CADD >15, 3) any missense variant, 4) any missense 
variant with CADD >15, and 5) any predicted loss-of-function (LOF) mutation (defined as stop-
gains, frameshift, core splice site alterations, stop-loss, or start-loss). For each filtered set, we first 
performed single-variant analysis using Fisher’s Exact Test within PLINK 1.9. We then used the 
R package SKAT (22) to perform burden and variance-component (i.e., SKAT) tests within 
genes. For each filtered variant set, we considered only those genes with ≥5 rare variants 
Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion  15 
 
observed in the 22q11.2DS European sample. We performed both unweighted and weighted 
analyses in a gene with the latter upweighting effects of extremely rare variants using a beta 
(0.5,0.5) distribution. For all analyses, we adjusted for sex, top 3 principal components of 
ancestry, total number of genome-wide variants, and PRS based on WGS data. 
In addition to gene-based analyses, we performed weighted and unweighted gene-set burden 
analyses with 30 functional pathways (Table S3) previously used to study CNV enrichment in 
schizophrenia, involving genes relevant to neuronal functions and synaptic components, or genes 
with homologues in mouse genes grouped by organ system (10). These analyses used the same 
filtering scheme described above and adjusted for multiple correlated tests using P_ACT (21). As 
a complementary analysis, we constructed logistic-regression models that, for a given pathway, 
assumed distinct effects for burden of LOF mutations and burden of missense variants passing or 
not passing CADD >15. We then used a likelihood-ratio statistic to test the null hypothesis that 
coefficients for all burden variables were equal to 0. These logistic-regression models used the 
same rare-variant weighting schemes and covariate adjustment as above. To adjust for multiple 
testing, we estimated the false discovery rate (FDR) based on outcome-label permutations 
balanced on covariates using the R package BiasedUrn (23). Finally, we also performed genome-
wide and deletion region-wide burden tests of global rare variation (i.e., regardless of gene 
function) between cases and controls using the same filtering schemes, variant-weighting 
schemes, and covariate adjustments as above.  
 
RESULTS  
22q11.2DS sample 
The main sample comprised 435 unrelated individuals of European ancestry with a 22q11.2 
deletion: 214 with schizophrenia (mean age at onset 22.1 (SD 8.3) years; mean age at assessment 
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30.9 (SD 12.8) years) and 221 with no lifetime diagnosis of psychotic disorder and age ≥25 years 
(mean age at assessment 36.4 (SD 10.0) years) (5). Sample characteristics are representative of 
those for all ethnicities (Table S4). Results for 22q11.2 deletion sizes showed the expected ~90% 
of subjects with the typical 2.5 Mb LCR22A–LCR22D 22q11.2 deletion (Fig. 1) (1, 5) and no 
significant difference in distribution between the two phenotypic subgroups (Χ2=0.0024, df=1, 
p=0.96).  
Genome-wide schizophrenia polygenic risk score (PRS) 
Using the PRS to analyze common variants collectively in 22q11.2DS showed that the PRS was 
significantly higher in those with schizophrenia than in those with no psychotic illness; 
significance was greatest using a p-value threshold (pT) of 0.05 to select individual SNPs from 
the training set (13) (Nagelkerke’s pseudo-R2 0.077, padjusted=6.73 x 10
-6). The risk of 
schizophrenia in individuals with 22q11.2DS increased by 1.77-fold (95% CI 1.41-2.22) for 
every incremental standard deviation in PRS (Fig. 2a and 2b; Table S5 shows results for other pT 
values). Using pT=0.05, individuals within the highest quartile of PRS had a 3.42-fold (95% CI: 
1.88-6.22) increased risk of schizophrenia compared to those in the lowest quartile (Fig. SF2). 
Using a subset of samples for which imputed data were available from microarray-based 
genotypes allowed us to directly compare schizophrenia PRS between 22q11.2DS (n=322; 147 
with schizophrenia, 175 without psychotic illness) and an idiopathic schizophrenia case-control 
cohort with no 22q11.2 deletion (10,791 schizophrenia CLOZUK cases, 24,391 WTCCC 
controls) (6). We first ensured the concordance of genotypes obtained by array and WGS (mean 
[median] variant concordance of 99.4% [99.6%]) and observed similar PRS distributions across 
methods (Fig. SF3); see Supplementary results for more details. Using this smaller sample and 
imputed data we again found significant differences in PRS for the 22q11.2DS schizophrenia 
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group compared to those with no psychotic illness (pT=0.05: R2=0.063, padjusted=5.5x10
-4, 
OR=1.63, 95% CI:1.27-2.08; Fig. 3a(i) and 3b(i)), confirming that the PRS results were 
comparable to those using WGS data. We also confirmed the significant difference in PRS 
between the CLOZUK-schizophrenia and the WTCCC-control samples, which was comparable 
to the results obtained when using larger case-control datasets (6, 13): pT=0.05: R2=0.11, padjusted 
<2x10-16, OR=2.05, 95% CI: 2.00-2.11; Fig. 3a(vi) and 3b(vi).  
We then proceeded to examine novel reciprocal case-control comparisons between the 
22q11.2DS and population-based cohorts (Fig. 1). Individuals with 22q11.2DS-schizophrenia had 
a significantly higher PRS than WTCCC-controls (pT=0.05: R2=0.014, padjusted 3.8x10
-6, 
OR=1.53, 95% CI: 1.29-1.81; Fig. 3a(ii) and 3b(ii)). Similarly, the CLOZUK-schizophrenia 
group had a significantly higher PRS than the 22q11.2DS-non-psychotic group (pT=0.05: 
R2=0.047, padjusted <2x10
-16, OR=2.05, 95% CI: 1.74-2.41; Fig. 3a(v) and 3b(v)). These results 
indicate that PRS was significantly greater in individuals with psychotic illness, regardless of the 
presence of the 22q11.2 deletion.  
Within diagnostic group analyses revealed that the PRS observed in schizophrenia cases from the 
CLOZUK cohort was significantly greater that that seen in those with schizophrenia and 
22q11.2DS (pT=0.05: R2=0.0065, padjusted 0.01, OR=1.31, 95% CI:1.10-1.55; Fig. 3a(iv) and 
3b(iv)). The PRS results for the non-psychotic 22q11.2DS group were not significantly different 
than those for WTCCC controls (Fig. 3a(iii) and 3b(iii)); however, the 22q11.2DS sample size 
was underpowered for this comparison given the low effect size (Table S6). 
We assessed the consistency of these results with a liability threshold model that assumed 
additive effects of the 22q11.2 deletion and PRS on risk for schizophrenia; details of our 
methodology and results are provided in the Supplemental methods and Table S7. The model that 
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best fit the observed data (where the sum of the absolute difference in observed and expected 
PRS was the lowest (0.005) across all 4 cohorts) estimated that the PRS contributes to 5.2% 
(range 4.9% to 5.5%) of the variance of liability for schizophrenia. This best-fit model also 
provided an estimate of the shift in liability attributable to the 22q11.2 deletion (1.0, range 0.2-
1.9) from population-based expectations of schizophrenia prevalence (2.33, based on top 1% CI 
of the normal distribution). In comparison, an increase in the PRS by one standard deviation 
corresponds to a shift in liability of 0.23. Working back from the estimated shift in liability 
attributable to the 22q11.2 deletion (i.e., 2.33–1.00=1.33) provides a predicted prevalence of 
schizophrenia in 22q11.2DS of 9.2% (range 1.7% to 33.7%) (Table S7). Using this best-fit 
liability threshold model to calculate the sample sizes required to provide 80% power to detect a 
nominally significant difference in PRS at pT=0.05, indicated that apart from the comparison of 
PRS between 22q11.2DS individuals without psychosis and WTCCC controls, all other primary 
analyses of polygenic risk were sufficiently powered (Table S6). 
Common variants - intact 22q11.2 allele and genome-wide association (GWAS) 
Given previous evidence for a genetic modifier locus in studies of cardiac phenotypes in 
22q11.2DS (24), we considered the possibility that individual genetic risk factors could confer an 
elevated effect size in association analyses of 22q11.2DS that compared those with and without 
schizophrenia. We examined this possibility by conducting association analyses of individual 
SNPs, restricted to the 22q11.2 deletion region (3,252 SNPs for full dataset, 3,236 SNPs for 
European ancestry) and genome-wide (4,313,064 SNPs outside this deletion region). None of 
these analyses identified genome-wide significant associations with schizophrenia in either the 
European cohort (n=435) or total cohort (n=519) (Fig. SF4 to SF9, Tables S8 to S11). Genome-
wide, the top SNP was rs12824373 (p=6.91x10-7), located in an intron of the CRADD gene. This 
SNP was not significantly associated with schizophrenia in the PGC GWAS (13). Also, no SNP 
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previously reported to reach genome-wide-significant levels of association with schizophrenia 
(13) yielded suggestive evidence of association in this GWAS of 22q11.2DS (minimum 
unadjusted p-value=7.4x10-3; Table S12). Results were also non-significant when restricting to 
724,010 SNPs in 2925 LOF-intolerant genes (6) (minimum p=4.88x10-5). 
Rare variants - individual, gene-based and gene-set analyses 
Similar to common variant results, there was no significant association of schizophrenia with any 
individual rare variant, nor for individual gene-based rare variant analyses, within or outside the 
22q11.2 deletion region (Fig. SF10, Table S13-15). There were few LOF variants within the 
22q11.2 deletion region (i.e., in effect, knock-out mutations) (Fig. 4).  
Analyzing genome-wide rare variants collectively in functional gene-sets (Table S3), comparable 
to methods used previously (5, 10), but with the addition of accounting for polygenic risk in 
22q11.2DS, showed nominally significant results (Table 1, Table S16). The top four results 
(unadjusted p values 5.9x10-3 – 5.5x10-4) implicated the Kirov_ARC gene-set (11, 25). Though 
none remained significant after adjustment for multiple testing, one result was borderline 
significant (p=0.053) after correcting for 300 tests (Table 1). Overall genome-wide rare-variant 
burden (i.e., regardless of gene function) showed no significant relationship to schizophrenia 
(unadjusted p values: genome-wide 0.35-0.79, 22q11.2 deletion region 0.02-0.79; Tables S17-
18). Similarly, there was no significant enrichment of heterozygous truncating variants (p=0.76) 
in a gene-set comprising 2,925 genes considered intolerant to LOF variation (gnomAD 2.1 
observed/expected LOF, upper 95% CI <0.35). 
Using a complementary multivariate method to assess the functional genome-wide rare variant 
burden supported the Kirov_ARC gene-set (11) as the most promising (permutation-based FDR 
~25%) of the 30 gene-sets tested, but revealed possible heterogeneity of findings (Fig. SF11). For 
rare missense variants in this gene-set, the coefficients were negative, indicating the variant 
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burden is enriched in the non-psychotic 22q11.2DS group. (Wald p-value, coefficient: 2.6x10-3, -
0.35 for missense CADD >15 variants; 0.04, -0.22 for other missense variants). In contrast, the 
contribution of LOF SNVs was positive (Wald p-value 0.21, coefficient 0.16), though non-
significant, suggesting that for the Kirov_ARC gene-set, the LOF rare variant burden may be 
somewhat enriched in those with schizophrenia. The main gene driving the putatively protective 
rare missense burden signal for the Kirov_ARC gene-set was DLGAP2 (gene-level nominal p-
value 0.01, CADD >15 missense variants).  
 
 
DISCUSSION  
The results of this study provide new data relevant to our understanding of the genetic 
architecture underlying the exceptionally increased risk for developing schizophrenia and related 
psychotic illnesses imparted by the 22q11.2 deletion (1). We demonstrate for the first time that 
individuals with 22q11.2DS who develop schizophrenia have a significantly greater 
schizophrenia polygenic risk score than those with no psychotic illness, suggesting that both the 
22q11.2 deletion and the aggregate risk conferred by common genetic risk factors outside the 
deleted region contribute to schizophrenia in 22q11.2DS. There was no evidence for 
contributions from common or rare variants at the individual variant or gene-based level. There 
was however some suggestive evidence that rare coding variants in genes involved in ARC 
synaptic gene complexes, previously reported to be involved in large population-based 
schizophrenia samples (8-12), may contribute to modifying risk of schizophrenia in 22q11.2DS.  
Contribution of genome-wide polygenic risk 
The PRS results showing that collective common genetic risk factors independent of the 22q11.2 
deletion have a substantive role in increasing risk of schizophrenia in 22q11.2DS are consistent 
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with research indicating the importance of polygenic risk in developing schizophrenia in large 
general population studies (6, 13). They are also consistent with findings for individuals with 
other CNVs that increase risk for neuropsychiatric and neurodevelopmental disorders (26-28). 
They differ somewhat from those of a study examining CNVs ascertained as part of the PGC that 
reported small PRS effects in 56 individuals with schizophrenia and a 22q11.2 deletion, in 
contrast to greater PRS effects for CNVs with low risk for schizophrenia that were also present in 
control samples (26). Availability of non-psychotic control groups and the sample sizes available 
could have contributed to the strong effect of schizophrenia PRS observed in our study. 
The ability to directly compare PRS between individuals with 22q11.2DS and cohorts of 
schizophrenia and controls with no 22q11.2 deletion allowed us to determine that the contribution 
of polygenic risk to schizophrenia was slightly but significantly lower in those with, than in those 
without a 22q11.2 deletion (6). This suggests that when our results are considered according to 
the liability threshold model, the presence of the 22q11.2 deletion may lower to some extent the 
degree of background polygenic risk involved in developing schizophrenia. 
Broad confidence intervals precluded our ability to determine additive or other relationships 
between the PRS and 22q11.2 deletion. Nonetheless, assuming an additive liability model, the 
proportion of variance liability for schizophrenia in 22q11.2DS attributable to the PRS was 
estimated to be 5.2% (range 4.9%-5.5%), which is in line with the estimates of 7% and 5.7% 
reported previously for idiopathic schizophrenia (6, 13). Based on this model there were wide 
ranges for the estimated shift in liability attributed to the 22q11.2 deletion (from the expected 1% 
population prevalence of schizophrenia) (Table S7) and estimated schizophrenia prevalence in 
22q11.2DS (1.7% to 33.7%). The latter values would therefore embrace the low estimates 
reported in other studies using statistical models (29, 30) and the actual observed prevalence of 
psychotic illness in 22q11.2DS of >20% (1, 31, 32).  
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Contribution of genome-wide rare variant functional gene-sets 
Complementary to the polygenic risk results, and in innovative analyses that accounted for PRS 
effects, the results also indicated a possible role for rare variants in the gene-set representing the 
ARC postsynaptic protein complex (8-12, 25). Consistent with our results in 22q11.2DS, effect 
sizes are expected to be modest for individual rare SNVs and related gene-set results in 
schizophrenia (25). It is therefore encouraging that our results for 22q11.2DS provided 
suggestive evidence in line with multiple studies that have reported rare variants, both SNVs and 
CNVs, affecting coding sequence of genes from the ARC and closely related synaptic gene-sets 
to be significantly associated with idiopathic schizophrenia (8-12, 29). Higher powered studies 
will be needed to evaluate the precise genomic architecture, including direction of effect patterns 
for rare variants (11, 25, 33, 34). 
Role of the 22q11.2 deletion and possible genetic mechanisms 
We have proposed that the presence of the 22q11.2 deletion may lower an individual’s tolerance 
for the expression of multiple biological mechanisms and/or pathways involved in developing 
schizophrenia (3, 5), and anticipate that this is likely to be related to the collective effect of 
lowered multi-gene dosage at the 22q11.2 locus. Importantly, we did not find evidence for risk 
attributable to the 22q11.2 deletion to be mediated through common or rare variants of genes 
located on the intact 22q11.2 allele, suggesting that it is unlikely that such variants have a large 
effect on schizophrenia risk. This included the few LOF (in effect null) variants that we identified 
(Fig. 4) and are now the focus of an in-depth reverse phenotyping effort. These negative results 
appear consistent with a recent study of idiopathic schizophrenia reporting the absence of 
detectable individual gene effects for 22q11.2 deletion genes, in contrast to genes in other CNV 
regions (35) . 
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Establishing the exact biological mechanisms through which the 22q11.2 deletion confers 
increased risk to schizophrenia is beyond the scope of this study. However, given the profile of 
the genes in this region, including those encoding transcription factors, mitochondrial proteins, 
and others, and the fact that most are expressed in brain (Fig. 4), the 22q11.2 deletion region may 
be particularly prone to general neurodevelopmental perturbation, and impaired regulatory 
mechanisms. For example, haploinsufficiency of DGCR8 affects miRNA buffering genome-
wide, thus could reveal or enhance effects of common and rare variants elsewhere in the genome 
(36-41). Many of the genes in the ARC gene-set, for example, are predicted to be affected by 
DGCR8 haploinsufficiency (36, 41).  
Large GWAS of schizophrenia indicate that the multiple SNPs involved at each significant locus 
are mostly intergenic or intronic, tag protein-coding and miRNA genes, and increase or decrease 
risk in about equal proportions, each with a very small effect size (6, 13). Thus the common 
variant signal measured by polygenic risk may be consistent with a role for non-coding and/or 
regulatory mechanisms in schizophrenia, including in 22q11.2DS (6, 13, 37, 41, 42). The precise 
complement of common and rare variants leading to schizophrenia may be personal to the 
individual but nonetheless observable in aggregate across individuals (43, 44). Further 
investigations designed to determine the exact nature of the primary 22q11.2 deletion-related 
biological insult therefore promises to improve our understanding of the mechanisms underlying 
schizophrenia in both 22q11.2DS and the general population. 
Advantages and limitations 
We had available the largest sample of 22q11.2DS subjects with and without a psychotic disorder 
ever brought together to study the impact of common and rare SNVs to schizophrenia risk. The 
signal imparted by additional polygenic common variant risk, similar to previous studies using 
idiopathic schizophrenia case-control samples several orders of magnitude larger (6, 13), 
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produced clearly significant results. The results support our design, using the non-psychotic 
22q11.2DS subgroup as the main comparison for 22q11.2DS cases with schizophrenia subgroup 
within 22q11.2DS. A power analysis indicated that our primary analyses of polygenic risk using 
the 22q11.2DS schizophrenia group were adequately powered for comparisons with 22q11.2DS 
without psychotic illness and with the large population-based case-control samples. Also, to our 
knowledge, this was the first study of schizophrenia genetics to account for polygenic risk while 
analyzing rare variant burden.  
Despite these advantages, power was limited by the available cohort size (Fig. SF12) and would 
be affected by the possibility that some 22q11.2DS subjects in the non-psychotic group may go 
on to develop schizophrenia. It is probable that some of the genome-wide polygenic risk 
associated with schizophrenia may also be involved in other neurodevelopmental disorders (45). 
This may make the current results all the more remarkable, given the presence of one or more 
neurodevelopmental phenotypes in most individuals with 22q11.2DS (46).  
With respect to rare variants, the current study focused primarily on the signal derived from the 
exome where findings are more likely to be biologically interpretable and potentially clinically 
relevant than that from non-coding variants (5, 33). Our conservative design, e.g., for each 
filtered variant set, considering only those genes with 5 or more rare variants observed in the 
22q11.2DS sample of European ancestry, and using 30 gene-sets thus correcting for 300 tests, 
may have affected power. Also, as in other sequencing studies (25), certain variant types, e.g., 
indels, were imperfectly captured (14). Recruiting larger samples of individuals with 
schizophrenia and older adults with no psychotic illness from the 22q11.2DS population could 
provide the means to further delineate the strength of the relationship between the factors 
identified, including rare variants in the small ARC gene-set, and the risk for schizophrenia. This 
would also be essential to enable investigation of other mechanisms with lower effect sizes. In 
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future studies, larger samples of 22q11.2DS may also assist in determining the role of X 
chromosome variants in the context of a 22q11.2 deletion, and provide sufficient data to assess 
those of non-European ancestry (5).  
Although we were unable to use these WGS data to simultaneously assess CNVs or other 
structural variants (14), we have previously demonstrated in a smaller but overlapping sample 
that additional rare CNVs overlapping genes outside of the 22q11.2 deletion region contribute to 
schizophrenia risk in 22q11.2DS (5). Also, the IBBC proband-only 22q11.2DS sample provides 
no capability of examining inheritance, parent-of-origin, or segregation data for the 22q11.2 
deletion or any other variants, or the family history of schizophrenia, all of which are factors of 
interest in disease expression (1, 3, 5). In smaller samples, the parental origin and inheritance 
status of the 22q11.2 deletion have not appeared to play a role in schizophrenia, however (47), 
and one can expect that >90% of the 22q11.2 deletions would arise as de novo mutations (1). 
CONCLUSIONS 
Our results indicate that, despite its high impact, the risk conferred by the 22q11.2 deletion is 
even greater when present with the genome-wide risk factors that also have a key role in 
schizophrenia risk in the general population (6, 13, 25). Given the magnitude of the risk of the 
22q11.2 deletion relative to common genetic risk factors, including polygenic risk, understanding 
the biological consequences of this deletion will be an important next step in appreciating the 
underlying pathology of schizophrenia. The overall results further illustrate the value of using 
22q11.2DS as a model for delineating the genetic architecture of schizophrenia. The direction of 
effect, and the type and precise position of the additional variants will be important factors to 
consider. Lessons learned from 22q11.2DS may be applicable to other recurrent CNVs that 
contribute to risk for schizophrenia in the general population (10). Future analyses of raw whole-
genome sequencing data will allow for more detailed assessment of variants and pathways 
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implicated, and the overall genetic architecture and proposed mechanisms of schizophrenia, 
incorporating those related to structural variants (5). These observations have important 
implications for research, including functional genomic studies using induced pluripotent stem 
cells from individuals with 22q11.2DS to model schizophrenia, and potentially for clinical 
genetic practice. Given the magnitude of the effect size of the 22q11.2 deletion, prospective 
studies using algorithms generated from such sequence data together with phenotypic data 
relevant to schizophrenia risk could lead to findings of clinical relevance to the individual (3, 48).  
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FIGURE LEGENDS 
Figure 1: IBBC 22q11.2 DS cohort overview and schematic of data generation and analyses 
performed. 
The full IBBC cohort and European subset are illustrated as yellow circles, broken down by 
numbers with or without schizophrenia, as well as sex and 22q11.2 deletion extent for individuals 
of European Ancestry. Whole-genome sequencing methods and data are represented by blue 
boxes and microarray data represented by green boxes (lighter for IBBC 22q11.2DS data, darker 
for schizophrenia case-control study data (15)). i to vi represent the comparisons presented in Fig. 
3 for novel reciprocal case-control comparisons of schizophrenia PRS between the 22q11.2DS 
and population-based cohorts.  
 
Figure 2. Polygenic risk score analyses of schizophrenia in 22q11.2DS.  
Analysis of schizophrenia PRS in 432 individuals of European ancestry with 22q11.2DS, with 
(n=212) or without (n=220) schizophrenia. Variants from the 22q11.2 deletion, MHC regions and 
X chromosome were excluded and results adjusted for sex, top 3 ancestry PCs. P-values were 
adjusted using P-ACT for the 13 p-value thresholds (pT) used for PRS construction (13). Details 
on the number of SNPs used (maximum 68,966 SNPs for polygenic risk scoring at pT=1, 
minimum 202 SNPs at pT=1x10-6) are shown in Table S9. Figure 2a. The proportion of variance 
in schizophrenia explained by PRS (Nagelkerke’s R2) across different pT thresholds. At 
pT=0.05, Nagelkerke’s pseudo-R2= 0.077 (adjusted p=6.73x10-6). Figure 2b. Odds ratio and 
95% confidence interval bars per one standard deviation increase in PRS across different pT 
thresholds. At pT=0.05 a one standard deviation increase in PRS corresponded to a 1.77-fold 
higher odds for schizophrenia in 22q11.2DS.  
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Figure 3. Polygenic risk score analyses in 22q11.2DS individuals with or without 
schizophrenia, and a case-control cohort without 22q11.2DS.  
PRS analyses were performed for 322 individuals with 22q11.2DS (147 with schizophrenia, 175 
without) and 35,182 individuals with no 22q11.2 deletion (10,791 schizophrenia CLOZUK cases, 
24,391 WTCCC controls) (6); all subjects were of European ancestry. 
Six comparisons of schizophrenia PRS were considered (Figure 1) between: (i) individuals with 
22q11.2DS, with and without schizophrenia (ii) 22q11.2DS-schizophrenia and WTCCC controls 
(iii) 22q11.2DS-non-psychotic and WTCCC controls (iv) the CLOZUK schizophrenia cohort and 
22q11.2DS-schizophrenia, (v) the CLOZUK schizophrenia cohort and 22q11.2DS-non-psychotic, 
and (vi) the CLOZUK schizophrenia cohort and WTCCC controls.  
Figure 3a shows the proportion of variance explained by PRS (Nagelkerke’s R2) for each of the 
six comparisons (clockwise: i to vi). Figure 3b shows the odds ratio and 95% confidence interval 
bars per PRS standard deviation constructed for these six PRS analyses (left to right: i to vi). 
Taken as a whole, these results demonstrate that the PRS in the CLOZUK-schizophrenia is 
significantly greater than that seen in 22q11.2DS individuals with schizophrenia, which itself is 
significantly greater than that seen in the WTCCC-controls and the 22q11.2DS non-psychotic 
groups. 
Figure 4. Representation of 46 genes spanning the 22q11.2 LCR22A-LCR22D deletion 
region annotated for contextual information and results from the current study:  
Representation of 46 genes spanning the 22q11.2 low copy repeat (LCR) LCR22A-LCR22D 
deletion region annotated for contextual information and, on grey background, results from the 
current study. The sections numbered 1-11 indicate the following: 
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1) Gene expression in brain, ranging from none to low (white) to low-medium (yellow) to 
medium-high (orange) to very high (red) according to BrainSpan (BrainSpan: Atlas of the 
Developing Human Brain [[http://developinghumanbrain.org]]http://developinghumanbrain.org]) 
and as previously processed by (10);  
2 & 3) Exome Aggregation Consortium (ExAC) (48) calculated probability (ranging from 0 to 
1.00, shown as a spectrum from white to deep violet) that the gene is intolerant to (2) two LOF 
variants (recessive; pRec), or (3) a single LOF variant (haploinsufficient; pLI);  
4 & 5) Neuro-phenotype data availability, (4) from mouse in the form of mouse homologues 
from MGI (49) as a union of two MPO-based gene-sets [MP:0005386 behavior/neurological 
phenotype, MP:0003631 nervous system phenotype] as used in (10), and (5) for human 
neurologic disease genes from the Clinical Genomic Database (CGD) (CGD: Clinical Genomic 
Database. [https://research.nhgri.nih.gov/CGD/]);  
6) Clusters of small rare deletions in the general population per the Database of Genomic 
Variants (DGV) (50), indicating presumed tolerance to hemizygosity, where an aqua circle/oval 
represents a single deletion cluster of ≤1% frequency;  
7) Rare LOF variants found in this 22q11.2DS cohort, thus representing a presumed null 
mutation, each variant observed in a single individual either within the schizophrenia (magenta) 
or non-psychotic (green) subgroups; number indicates the number of individuals (1, 2, or 3) in the 
schizophrenia or non-psychotic group with a LOF variant identified;  
8) Genes in the 22q11.2 deletion region that show nominal significance for rare variants (in 
yellow, p-values ranged between 7.92E-03 and 4.75E-02 based on SKAT or Burden test) or for 
common variants (in red, p-values ranged between 3.63E-03 and 4.23E-02 based on SKAT test) 
in gene-based association tests for schizophrenia in this study using data for the subset of 
European ancestry. All results for the SKAT gene-based test for common variants can be found 
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in Table S19. Note that all genes with nominal significance for rare variants are indicated in 
yellow, but that only CDC45, PI4KA, CLTCL1 and TRMT2A comply with the n≥5 rare variants 
criterion (see Table S15 for exact number of rare variants).   
9) Schematic of gene positions in the 22q11.2 region. 
10) Schematic of the positions, relative to genes, of the main 22q11.2 deletion region LCR22s A, 
B, C, and D.  
11) Approximate genomic extents of the two most common 22q11.2 deletion sizes.  
NA = Data not available. 
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TABLES 
 
Table 1. Gene-set burden association results for rare variants in Kirov ARC pathway and 
schizophrenia in 432 European subjects with 22q11.2DS 
 
Burden (SKAT) 
Variant group and weight P-value Adjusted P-value (FWER)* 
Missense – any 0.00055 0.053 
Missense – any, weighted 
for rarity 
0.0028 0.22 
Any with CADD > 15 0.0045 0.31 
Missense with CADD > 15 0.0059 0.37 
 
Burden (Logistic Regression)*** 
Variant group Coefficient 
point estimate 
Coefficient 
Ward P-value 
Global P-value Adjusted P-value 
(permutation-
FDR)** 
LOF Indel NA NA 0.0012 0.25 
LOF SNV 0.17 0.12 
Missense with 
CADD > 15 
-0.30 0.0065 
Missense other -0.22 0.034 
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* Adjusted p-value based on multiple test correction using P_ACT for the 300 tests conducted 
(30 gene-sets (10) x 5 variant filters x 2 weighting schemes) 
** Adjusted p-value based on multiple test correction using permutation-based FDR for 1000 
iterations of 360 tests (30 gene-sets (10) x 2 variant sets x 3 frequency weighting schemes x 2 
PRS and no PRS) 
*** Burden result based on a logistic regression model combines effects from different types of 
rare variants (LOF Indel, LOF SNV, Missense with CADD > 15 and Missense other) with PRS 
as one of the covariates 
Kirov_ARC = 28 genes in an activity-regulated cytoskeleton-associated protein (ARC) complex 
curated by George Kirov in 2012 (11).  




